-
1دورية أكاديمية
-
2دورية أكاديمية
المؤلفون: Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, Todoerti K, Al-Janazreh H, D’Arrigo G, Canale FA, Cutrona G, Neri A, Martino M, Gentile M
المصدر: Drug Design, Development and Therapy, Vol Volume 15, Pp 2969-2978 (2021)
مصطلحات موضوعية: multiple myeloma, relapsed resistant, melphalan flufenamide, melflufen, therapy, melphalan, Therapeutics. Pharmacology, RM1-950
وصف الملف: electronic resource
العلاقة: https://www.dovepress.com/spotlight-onTest-melphalan-flufenamide-an-up-and-coming-therapy-for-the-tr-peer-reviewed-fulltext-article-DDDT; https://doaj.org/toc/1177-8881Test
-
3دورية أكاديمية
المؤلفون: Gebraad, Arjen, Ohlsbom, Roope, Miettinen, Juho J., Emeh, Promise, Pakarinen, Toni-Karri, Manninen, Mikko, Eskelinen, Antti, Kuismanen, Kirsi, Slipicevic, Ana, Lehmann, Fredrik, Nupponen, Nina N., Heckman, Caroline A., Miettinen, Susanna
المساهمون: Institute for Molecular Medicine Finland, University of Helsinki, Helsinki Institute of Life Science HiLIFE, Research Programs Unit, Digital Precision Cancer Medicine (iCAN)
مصطلحات موضوعية: melflufen, melphalan flufenamide, peptide-drug conjugate, mesenchymal stem, stromal cells, multiple myeloma, bone marrow, drug sensitivity, osteogenesis, adipogenesis, angiogenesis, FLUOROPHENYLALANINE ETHYL-ESTER, ALKYLATING PRODRUG J1, ANGIOGENESIS IN-VITRO, STEM-CELLS, OSTEOGENIC DIFFERENTIATION, ANTITUMOR EFFICACY, ENDOTHELIAL-CELLS, AMINOPEPTIDASE-N, EX-VIVO, 1182 Biochemistry, cell and molecular biology
وصف الملف: application/pdf
العلاقة: This research was funded by the Academy of Finland, Centre of Excellence in Body-on-aChip research (grant numbers 312413, 326588, 336666 and 336785), Business Finland, YCompetitive State Research Financing of the Expert Responsibility area of Tampere University Hospital, and Finnish National Agency for Education.; Gebraad , A , Ohlsbom , R , Miettinen , J J , Emeh , P , Pakarinen , T-K , Manninen , M , Eskelinen , A , Kuismanen , K , Slipicevic , A , Lehmann , F , Nupponen , N N , Heckman , C A & Miettinen , S 2022 , ' Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen ' , Cells , vol. 11 , no. 9 , 1574 . https://doi.org/10.3390/cells11091574Test; ORCID: /0000-0002-3987-1693/work/113985832; 4c5cf765-fadd-4e8c-907e-c6ae4c623819; http://hdl.handle.net/10138/344210Test; 000794431900001
-
4دورية أكاديمية
المؤلفون: Arjen Gebraad, Roope Ohlsbom, Juho J. Miettinen, Promise Emeh, Toni-Karri Pakarinen, Mikko Manninen, Antti Eskelinen, Kirsi Kuismanen, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Caroline A. Heckman, Susanna Miettinen
المصدر: Cells; Volume 11; Issue 9; Pages: 1574
مصطلحات موضوعية: melflufen, melphalan flufenamide, peptide–drug conjugate, mesenchymal stem/stromal cells, multiple myeloma, bone marrow, drug sensitivity, osteogenesis, adipogenesis, angiogenesis
وصف الملف: application/pdf
-
5دورية أكاديمية
المصدر: Pharmaceuticals; Volume 15; Issue 2; Pages: 222
مصطلحات موضوعية: drugs, FDA, oligonucleotides, peptides, antibody-drug conjugate, inclisiran, casimersen, vosoritide, melphalan flufenamide, voclosporin, pegcetacoplan, dasiglucagon, Piflufolastat-F 18, difelikefalin, odevixibat, tisotumab vedotin-tftv, loncastuximab tesirine-lpyl
وصف الملف: application/pdf
العلاقة: Medicinal Chemistry; https://dx.doi.org/10.3390/ph15020222Test
-
6دورية أكاديمية
المؤلفون: Al Shaer, D, Almusaimi, O, Albericio, F, De la Torre, BG
مصطلحات موضوعية: FDA, Piflufolastat-F18, antibody-drug conjugate, casimersen, dasiglucagon, difelikefalin, drugs, inclisiran, loncastuximab tesirine-lpyl, melphalan flufenamide, odevixibat, oligonucleotides, pegcetacoplan, peptides, tisotumab vedotin-tftv, voclosporin, vosoritide, 1115 Pharmacology and Pharmaceutical Sciences
العلاقة: Pharmaceuticals; http://hdl.handle.net/10044/1/95772Test
-
7دورية أكاديمية
المؤلفون: Larocca A., Leleu X., Touzeau C., Blade J., Paner A., Mateos M. -V., Cavo M., Maisel C., Alegre A., Oriol A., Raptis A., Rodriguez-Otero P., Mazumder A., Laubach J., Nadeem O., Sandberg A., Orre M., Torrang A., Bakker N. A., Richardson P. G.
المساهمون: Larocca A., Leleu X., Touzeau C., Blade J., Paner A., Mateos M.-V., Cavo M., Maisel C., Alegre A., Oriol A., Raptis A., Rodriguez-Otero P., Mazumder A., Laubach J., Nadeem O., Sandberg A., Orre M., Torrang A., Bakker N.A., Richardson P.G.
مصطلحات موضوعية: health-related quality of life, melflufen, melphalan flufenamide, patient-reported outcome, relapsed/refractory multiple myeloma, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocol, Biomarkers, Tumor, Dexamethasone, Female, Human, Male, Melphalan, Middle Aged, Multiple Myeloma, Neoplasm Grading, Neoplasm Staging, Patient Reported Outcome Measure, Treatment Outcome
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34671975; info:eu-repo/semantics/altIdentifier/wos/WOS:000709242300001; volume:196; issue:3; firstpage:639; lastpage:648; numberofpages:10; journal:BRITISH JOURNAL OF HAEMATOLOGY; http://hdl.handle.net/2318/1846953Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85117392564; https://doi.org/10.1111/bjh.17887Test
-
8
المؤلفون: Mateos, Maria-Victoria, Blade, Joan, Bringhen, Sara, Ocio, Enrique M., Efebera, Yvonne, Pour, Ludek, Gay, Francesca, Sonneveld, Pieter, Gullbo, Joachim, Richardson, Paul G.
المصدر: Journal of Clinical Medicine. 9(10)
مصطلحات موضوعية: melflufen, melphalan flufenamide, peptide–, drug conjugate, multiple myeloma, new drugs, drug combinations
وصف الملف: electronic
الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-426962Test
https://doi.org/10.3390/jcm9103120Test
https://uu.diva-portal.org/smash/get/diva2:1506193/FULLTEXT01.pdfTest -
9دورية أكاديمية
المؤلفون: Morabito, Fortunato, Tripepi, Giovanni, Martino, Enrica Antonia, Vigna, Ernesto, Mendicino, Francesco, Morabito, Lucio, Todoerti, Katia, Al-Janazreh, Hamdi, D'Arrigo, Graziella, Canale, Filippo Antonio, Cutrona, Giovanna, Neri, Antonino, Martino, Massimo, Gentile, Massimo
المساهمون: F. Morabito, G. Tripepi, E.A. Martino, E. Vigna, F. Mendicino, L. Morabito, K. Todoerti, H. Al-Janazreh, G. D'Arrigo, F.A. Canale, G. Cutrona, A. Neri, M. Martino, M. Gentile
مصطلحات موضوعية: Melflufen, Melphalan, Melphalan flufenamide, Multiple myeloma, Relapsed resistant, Therapy, Settore MED/15 - Malattie del Sangue
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/34262262; info:eu-repo/semantics/altIdentifier/wos/WOS:000671357500001; volume:15; firstpage:2969; lastpage:2978; numberofpages:10; journal:DRUG DESIGN, DEVELOPMENT AND THERAPY; http://hdl.handle.net/2434/860025Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85110925941
-
10دورية أكاديمية
المؤلفون: Bringhen, Sara, Voorhees, Peter M., Plesner, Torben, Mellqvist, Ulf-Henrik, Reeves, Brandi, Sonneveld, Pieter, Byrne, Catriona, Nordström, Eva, Harmenberg, Johan, Obermüller, Jakob, Richardson, Paul G.
المصدر: Bringhen , S , Voorhees , P M , Plesner , T , Mellqvist , U-H , Reeves , B , Sonneveld , P , Byrne , C , Nordström , E , Harmenberg , J , Obermüller , J & Richardson , P G 2021 , ' Melflufen plus dexamethasone in relapsed/refractory multiple myeloma : long-term survival follow-up from the Phase II study O-12-M1 ' , British Journal of Haematology , vol. 193 , no. 6 , pp. 1105-1109 . https://doi.org/10.1111/bjh.17302Test
مصطلحات موضوعية: melflufen, melphalan flufenamide, multiple myeloma, relapsed/refractory multiple myeloma
وصف الملف: application/pdf
العلاقة: https://portal.findresearcher.sdu.dk/da/publications/7450af80-416c-4eb6-81a4-d4b45012693dTest
الإتاحة: https://doi.org/10.1111/bjh.17302Test
https://portal.findresearcher.sdu.dk/da/publications/7450af80-416c-4eb6-81a4-d4b45012693dTest
https://findresearcher.sdu.dk/ws/files/190556676/Open_Access_Version.pdfTest